A. Garcia-Basteiro (Maputo, Mozambique), A. dos Santos Silva (Porto, Portugal), M. Pretti Dalcolmo (Rio De Janeiro (RJ), Brazil), A. Skrahina (Minsk region, Belarus)
Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection. I. Chernokhaeva (St.-Petersburg, Russian Federation), E. Ershova (St.-Petersburg, Russian Federation), M. Pavlova (St.-Petersburg, Russian Federation), A. Starshinova (St.-Petersburg, Russian Federation), N. Sapozhnikova (St.-Petersburg, Russian Federation)
|  |
Bedaquiline in the treatment of patients with co-infection HIV/tuberculosis A. Galstyan (Moscow, Russian Federation), S. Borisov (Moscow, Russian Federation), M. Sinitsin (Moscow, Russian Federation)
|   |
Bedaquiline in treatment of TB/HIV co-infection patients with extremely-drug resistance of MBT G. Balasaniantc (Saint-Petersburg, Russian Federation)
|  |
To evaluate the outcome of tuberculosis at a tertiary care hospital in Karachi-Pakistan S. Zubair (Karachi, Pakistan), M. Gohar (Karachi, Pakistan), T. Shahzad (Karachi, Pakistan), A. Yaseen (Karachi, Pakistan), M. Irfan (Karachi, Pakistan)
|  |
Spreading of resistance to group A anti-tuberculosis drugs among TB patients in Astana city G. Balasaniantc (Saint-Petersburg, Russian Federation), Z. Rakisheva (Astana, Kazakhstan), A. Zepke (Astana, Kazakhstan), A. Akisheva (Astana, Kazakhstan), N. Solovjeva (Saint-Petersbusg, Russian Federation)
|  |
Evaluation of 123 Cases with MDR TB (Multidrug Resistant Tuberculosis) Treatment A. Babalik (Istanbul, Turkey), A. Rumeysa Hazine (Istanbul, Turkey), G. Erdal Donmez (Istanbul, Turkey), O. Akkan (Istanbul, Turkey), F. Kutluhan (Istanbul, Turkey), A. BaliKci (Istanbul, Turkey), G. Catmabacak (Istanbul, Turkey), K. Koksalan (Istanbul, Turkey), T. Kuyucu (Istanbul, Turkey)
|  |
Nature, Magnitude and Risk Factors of Adverse Drug Reactions in Multidrug Resistant TB Patients in Eritrea M. Russom (Asmara, Eritrea), K. Verhamme (Rotterdam, Netherlands), L. Karimi (Rotterdam, Netherlands), H. Ahmed (Asmara, Eritrea)
|  |
Accompanying therapy of patients with extensive drug-resistant (xdr) lung tuberculosis L. Shovkun (Rostov-on-Don, Russian Federation), D. Kudlay (Moscow, Russian Federation), N. Nikolenko (Moscow, Russian Federation), I. Franchuk (Rostov-on-Don, Russian Federation)
|   |
MDR-TB treatment efficacy by results of Xpert MTB/RIF assayin the Stavropol region of the Russian Federation O. Komissarova (Moscow, Russian Federation), R. Abdullaev (Moscow, Russian Federation), Y. Chumakova (Moscow, Russian Federation), V. Odinets (Moscow, Russian Federation)
|   |
Community based therapy for children with Multidrug-Resistant Tuberculosis in Khyber Pakhtunkhwa Peshawar, Paksitan A. Javaid (Peshawar, Pakistan), M. Khan (Peshawar, Pakistan), M. Khan (Peshawar, Pakistan)
|  |
Use of shortened chemotherapy regimens in treatment of adolescents with MDR/XDR TB E. Viechelli (Moscow, Russian Federation)
|  |
Adverse effects of chemotherapy in patients with multidrug-resistant tuberculosis with alcohol abuse and without one A. Aleksa (Grodno, Belarus), I. Gelberg (Grodno, Belarus), S. Wolf (Grodno, Belarus), J. Artsukevich (Grodno, Belarus), A. Tsiunchyk (Grodno, Belarus), A. Masilevich (Grodno, Belarus), Y. Shejfer (Grodno, Belarus)
|  |
Use of line probe assays for the diagnosis of drug-resistant tuberculosis in Hospital for respiratory diseases “St. Sofia”, Sofia, Bulgaria V. Milanov (Sofia, Bulgaria), S. Velizarova (Sofia, Bulgaria), A. Spasova (Sofia, Bulgaria), N. Gabrovska (Sofia, Bulgaria), T. Dimitrova-Milanova (Sofia, Bulgaria), G. Mihaylova (Sofia, Bulgaria), M. Nachkova (Sofia, Bulgaria), D. Kostadinov (Sofia, Bulgaria)
|  |
Variability of primary resistant M.tuberculosis strains in TB service institutions A. Rogozhin (Kharkiv, Ukraine), P. Poteiko (Kharkiv, Ukraine), O. Konstantynoska (Kharkiv, Ukraine), O. Liashenko (Kharkiv, Ukraine), O. Solodiankin (Kharkiv, Ukraine)
|  |
Construing the role of Proteasome Accessory Factor-C in fluoroquinolone resistance in pulmonary tuberculosis A. NARAIN (Lucknow, India), E. Dhamija (Lucknow, India), K. Srivastava (Lucknow, India), K. Srivastava (Lucknow, India), S. Kant (Lucknow, India)
|   |
A case series of pyrazinamide mono-resistant mycobacterium tuberculosis using whole genome sequencing for diagnosis and cluster linkage. D. Braganza Menezes (Birmingham, United Kingdom), S. Lugg (Birmingham, United Kingdom), G. Hawthorne (Birmingham, United Kingdom), E. Robinson (Birmingham, United Kingdom), M. Dedicoat (Birmingham, United Kingdom)
|   |
Ability of genotypical method to make assesment of tuberculosis infection hotbed O. Hovardovska (Kharkiv, Ukraine), O. Schevchenko (Kharkiv, Ukraine), I. Ovcharenko (Kharkiv, Ukraine)
|  |